Enterprise record

Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:eed78fab-8a67-4bbc-a621-d77f4e600d2eVersion: public-1As of: unavailable

29 published Claims4 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 3 claims
    • Legal Name: Arcus Biosciences, Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026

  2. SEC DEF 14A 0001724521-26-000025

    sec def 14a · Source published: Apr 21, 2026 · Retrieved: Sep 12, 2026

    Supports 14 claims
    • Leadership Role: Terry Rosen, Ph.D.: Chief Executive Officer, Director and Chairman · Claim reviewed: Sep 29, 2026
    • Leadership Role: Andrew Perlman, M.D., Ph.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Antoni Ribas, M.D., Ph.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: David Lacey, M.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Dietmar Berger, M.D., Ph.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Johanna Mercier: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Linda Higgins, Ph.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Patrick Machado, J.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Yasunori Kaneko, M.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Carolyn Tang: General Counsel · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jennifer Jarrett: Chief Operating Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Juan Carlos Jaen, Ph.D.: President · Claim reviewed: Sep 29, 2026
    • Leadership Role: Richard Markus, M.D., Ph.D.: Chief Medical Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Terry Rosen, Ph.D.: Chief Executive Officer · Claim reviewed: Sep 29, 2026

  3. DEF 14A rcus-20260421.htm

    sec proxy · Source published: Apr 21, 2026 · Retrieved: Sep 2, 2026

    Supports 10 claims
    • Leadership Role: Andrew Perlman: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: David Lacey: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Dietmar Berger: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Kathryn Falberg: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Nicole Lambert: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Patrick Machado: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Terry Rosen: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Yasunori Kaneko: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Robert C. Goeltz: Chief Financial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Terry Rosen: Chief Executive Officer and Director · Claim reviewed: Sep 29, 2026

  4. RCUS DEF 14A executive officers

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Leadership Role: Richard B. Cassidy II: Chief Financial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Thilo Schroeder, Ph.D.: Chief Executive Officer, Director and Chairman · Claim reviewed: Sep 29, 2026